Brexanolone (Zulresso) was the first drug ever FDA-approved specifically for postpartum depression (2019). Given as a 60-hour IV infusion in a certified healthcare setting, it can lift moderate-to-severe PPD within days by acting on the brain’s GABA system.
Educational information, not medical advice. This page summarizes published research and public-health guidance for learning purposes. It is not a substitute for diagnosis or treatment by a qualified clinician. If you are struggling, talk to your doctor or midwife. In a crisis, call or text 988 or the Maternal Mental Health Hotline at 1-833-852-6262.
Evidence snapshot — computed from live data
174
Studies indexed (PubMed)
moderate evidenceStrength score 56/100
What makes it different
Unlike SSRIs, brexanolone is a neuroactive steroid that mimics allopregnanolone—a hormone that plummets after birth. It works rapidly, often within the 60-hour infusion, rather than over weeks.
How it’s given
It requires continuous IV infusion over about 2.5 days at a certified center with monitoring, because of the risk of excessive sedation. This intensity limits its use to specific moderate-to-severe cases.
See how this fits alongside other options in our treatment overview, and the medications used for PPD in the medication guide.
Sources & further reading
Selected recent peer-reviewed studies, pulled live from the U.S. National Library of Medicine (PubMed). Counts and citations update automatically.
- Dargan TL et al. “Potential of Neurosteroids for Precision Medicine in Psychiatry.” Biological psychiatry (2026). PubMed →
- Xie G et al. “Real-world adverse event profiles of Zuranolone and Brexanolone based on FAERS and VigiAccess databases: An observational study.” Medicine (2026). PubMed →
- Xiao Y et al. “Comparative efficacy and acceptability of pharmacological interventions for postpartum depression: a systematic review and network meta-analysis.” Psychiatry research (2026). PubMed →
- Ok HI et al. “First Reported Case of Dissociative Symptoms Associated With Zuranolone Use in Peripartum Depression.” Cureus (2026). PubMed →
- Lyu G et al. “Innovations in Depression Diagnosis and Treatment: A Review of Biological, Cognitive, and Psychosocial Advances.” Current topics in medicinal chemistry (2026). PubMed →